Category: Asean

• ดร. Santiago Munné ผู้บุกเบิกการวินิจฉัยโรคทางพันธุกรรมระยะก่อนการฝังตัวของตัวอ่อน ได้นำเสนอการทดสอบใหม่ในการประชุม PGDIS
• การทดสอบในห้องปฏิบัติการใหม่นี้จะไม่เพียงแต่ตรวจจับยีนที่สืบทอดมาจากพ่อแม่เท่านั้น แต่ยังเผยให้เห็นการกลายพันธุ์ใหม่ที่อาจนำไปสู่โรค ‘de novo’ เช่น ออทิสติกอีกด้วย

ปารีส, April 20, 2023 (GLOBE NEWSWIRE) — ดร. Santiago Munné ผู้บุกเบิกด้านการวินิจฉัยโรคทางพันธุกรรมระยะก่อนการฝังตัวของตัวอ่อน ได้นำเสนอการทดสอบลำดับจีโนมทั้งหมดในตัวอ่อนเป็นครั้งแรกต่อหน้าผู้แทนในการประชุมสมาคมวินิจฉัยโรคทางพันธุกรรมระยะก่อนการฝังตัวของตัวอ่อนระหว่างประเทศ (PGDIS) ครั้งที่ 20 ซึ่งจัดขึ้นในสัปดาห์นี้ที่กรุงปารีส

ดร. Munné ซึ่งเป็นผู้บุกเบิกด้านพันธุศาสตร์การสืบพันธุ์ที่ได้รับการยอมรับในระดับสากล ได้นำเสนอข้อมูลการตรวจสอบความถูกต้องสำหรับ GenomeScreen ซึ่งเป็นการทดสอบที่พัฒนาโดยทีมวิจัยที่เขาเป็นผู้นำในบริษัทเทคโนโลยีชีวภาพ GenEmbryomics โดยกล่าวในคำปราศรัยแบบครบถ้วนของเขาที่มีผู้เชี่ยวชาญกว่า 300 คนเข้าร่วม

“เรารู้ตั้งแต่เริ่มทำงานกับการวินิจฉัยตัวอ่อนในปี 2536 ว่าการเลือกตัวอ่อนจะเป็นกุญแจสำคัญในการตั้งครรภ์ โดยเฉพาะอย่างยิ่งในผู้ป่วยสูงอายุ กว่า 30 ปีที่ผ่านมา งานของเรามุ่งเน้นไปที่การปรับปรุงการคัดเลือกตัวอ่อนทางพันธุกรรม แม้ว่าแนวทางการวินิจฉัยขั้นสุดท้ายซึ่งให้ข้อมูลมากที่สุดและผลลัพธ์ที่ดีที่สุดจะเป็นแนวทางนี้อย่างไม่ต้องสงสัย นั่นคือ การจัดลำดับจีโนมทั้งหมดของตัวอ่อนโดยใช้เพียง เซลล์บางส่วนที่ได้จากการตรวจชิ้นเนื้อ การทดสอบนี้จะเปิดประตูที่เราไม่เคยรู้จักมาก่อน” Munné กล่าวถึงงานที่มีการทำที่ GenEmbryomics

การทำความเข้าใจเกี่ยวกับจีโนมคือการรู้ทุกอย่างเกี่ยวกับตัวอ่อนก่อนการย้าย
GenomeScreen เป็นการปฏิวัติการทดสอบลำดับจีโนมใหม่ทั้งหมดสำหรับตัวอ่อน IVF (เด็กหลอดแก้ว) ที่ได้รับการอธิบายโดยหน่วยงานที่ฟอรัม PGDIS ว่าเป็น “การทดสอบทางพันธุกรรมที่สมบูรณ์แบบที่สุดในด้าน IVF”

การทดสอบให้ข้อมูลที่แม่นยำสูงเกี่ยวกับลำดับจีโนมของตัวอ่อนและพ่อแม่ทางพันธุกรรม โดยนำเสนอข้อมูลเชิงลึกด้านก่อนการฝังตัวที่สำคัญที่เกี่ยวกับสุขภาพของตัวอ่อนและการพยากรณ์โรคในระบบสืบพันธุ์แก่ครอบครัว ซึ่งสามารถแจ้งข้อมูลการตัดสินใจของครอบครัวได้ นอกจากนี้ ข้อมูลนี้จะเป็นประโยชน์อย่างยิ่งต่อบุคคลที่เกิดจากการทำ IVF เนื่องจากจะให้ข้อมูลด้านโภชนาการหรือคำแนะนำว่ายาชนิดใดที่เหมาะกับผู้ป่วยมากที่สุด

Dr. Nick Murphy ผู้ก่อตั้ง GenEmbryomics กล่าวว่า “เมื่อเราเริ่มการวิจัยเกี่ยวกับการหาลำดับตัวอ่อนครั้งแรก เป้าหมายของเราคือการสร้างเครื่องมือที่ทรงพลังและครอบคลุม ซึ่งจะช่วยให้แพทย์ด้านการเจริญพันธุ์ได้รับข้อมูลที่ละเอียดถี่ถ้วนเพื่อการตรวจคัดกรองที่แม่นยำ” “ตอนนี้เรามีเครื่องมือนี้และใช้งานได้ด้วยความน่าเชื่อถือ 99% เราทราบดีว่าการวินิจฉัยนี้ไม่เพียงแต่ให้ข้อมูลเท่านั้น แต่ยังช่วยเพิ่มความสำเร็จของเวชศาสตร์การเจริญพันธุ์ด้วย” Murphy กล่าวเสริม

การจัดลำดับตัวอ่อนจะเพิ่มอัตราความสำเร็จในการทำ IVF

ศาสตราจารย์ Munné ซึ่งเป็นผู้นำด้านพันธุศาสตร์การเจริญพันธุ์ทำงานมากว่า 20 ปี ได้มีส่วนช่วยเหลืออย่างมากในการคัดเลือกตัวอ่อนและการรักษาด้าน IVF ศาสตราจารย์และทีมนักวิจัยได้เสริมบทบาทของการทดสอบทางพันธุกรรมในเวชศาสตร์การเจริญพันธุ์ด้วยการทดสอบนี้ และช่วยเพิ่มความสำเร็จในการรักษา

Munné กล่าวว่า “การค้นพบที่นำเสนอในที่ประชุมเป็นข้อมูลการตรวจสอบสำหรับการทดสอบที่จะเปลี่ยนการคัดเลือกตัวอ่อนตามที่เราทราบ” ศาสตราจารย์กล่าวสรุปว่า “การวิเคราะห์พันธุกรรมก่อนการฝังตัวด้วยการจัดลำดับจีโนมทั้งหมดเป็นก้าวสำคัญเหนือสิ่งอื่นใด ซึ่งจะบอกเราว่าตัวอ่อนตัวใดจะฝังได้สำเร็จ เพราะเราจะทราบล่วงหน้าว่าตัวใดมีสุขภาพที่แข็งแรงได้อย่างแท้จริง ซึ่งหมายความว่าเราจะรู้ว่าตัวอ่อนใดที่ปราศจากโรคที่สืบทอดมาจากพ่อแม่ หรือโรคเดโนโว เช่น ออทิสติก เป็นต้น”

เกี่ยวกับ GenEmbryomics
GenEmbryomics ก่อตั้งโดย ดร. Nick Murphy ในปี 2562 เป็นบริษัทเทคโนโลยีชีวภาพที่ล้ำสมัยซึ่งเชี่ยวชาญด้านการวิเคราะห์จีโนมของตัวอ่อนเพื่อระบุตัวอ่อนที่เหมาะสมที่สุดสำหรับการฝัง IVF งานขององค์กรจะนำไปสู่อัตราความสำเร็จที่สูงขึ้นในรอบการทำ IVF เนื่องจากอัลกอริทึมที่เป็นกรรมสิทธิ์ขององค์กรที่มอบการเลือกตัวอ่อนที่แม่นยำและมีประสิทธิภาพมากขึ้นโดยพิจารณาจากจีโนมทั้งหมดของตัวอ่อนแต่ละตัว

สำหรับข้อมูลเพิ่มเติม
Dulce Iborra Candela
+34 647942875
dulce@laembajadora.es

GlobeNewswire Distribution ID 8811736

MILAN, Italy, April 19, 2023 (GLOBE NEWSWIRE) — Edison Energia, an Edison Group company active in the sale of electric power and natural gas to households and businesses and value-added services to the retail market, reached 2 million contracts including residential, SME and industrial customers, thereby consolidating its third position in the national market in terms of volumes of electric power and its second position in terms of volumes of natural gas sold. The company’s goal, through its strategic development plan to 2030, is to double the number of contracts to 4 million between commodities, energy efficiency services and products (photovoltaic technology, heat pumps, boilers and climate), electric mobility solutions and insurance products for the protection of domestic systems.

At the event to present the plan and celebrate the milestone, Nicola Monti, CEO of the Edison Group, explained that the group has “a strategic plan with three main growth axes between now and 2030”: renewables, natural gas and the growth of all market activities. Monti continued: “We are very satisfied with the goals achieved by Edison Energia, a company that best expresses the corporate values of quality, innovation and competence at the service of the domestic and industrial sectors.” The group’s CEO added that, “Edison is an operator committed to the ecological transition of our country through the entire industrial chain from generation to the marketing of energy products and services to all market segments.”

The goal is to achieve 4 million contracts by 2030, mainly through organic development but also through non-organic growth opportunities, with the acquisition of large and small companies – as has already happened between 2018 and 2022 with Gas Natural, Attiva, Energia Etica and Gaxa – as well as through participation in auctions following the end of the protected market. According to the CEO of Edison Energia, Massimo Quaglini, “today more than ever people are looking for a relationship based on trust, reliability and soundness of the supplier. Our unique 140-year history of excellence in the sector qualifies us to be a partner capable of fully satisfying these needs of our customers: we accompany families and businesses in learning about and progressively adopting increasingly advanced solutions for a conscious and sustainable energy consumption for all”, all this in a context in which the energy crisis and the concerns triggered by the scarcity of raw materials “have profoundly changed the behaviour in the purchasing choices of families and businesses”.

For more information:
Press Office LaPresse – ufficio.stampa@lapresse.it

A video accompanying this announcement is available at: https://www.globenewswire.com/NewsRoom/AttachmentNg/2f3bf836-7bb1-4e19-8998-ffa8c1261fa8

GlobeNewswire Distribution ID 8811009

Zero-trust cybersecurity demand drives business and operational growth for leading critical infrastructure protection solution provider

Tokyo, Japan, April 18, 2023 (GLOBE NEWSWIRE) — OPSWAT, the global leader in Critical Infrastructure Protection (CIP) cybersecurity solutions, announces its continued business expansion and operational growth in Japan due to rising demand for zero-trust cybersecurity solutions that protect critical infrastructure. OPSWAT also appoints Atsushi Takamatsu as the new Country General Manager, Japan, with the objective of spearheading operational excellence and accelerating OPSWAT’s penetration of the OT security market in the region.

OPSWAT attributes this growth to its strategic alliance with Net One Partners K.K. in driving the company’s IT and OT cybersecurity market expansion across Japan. OPSWAT’s customer growth has reached 190% year-over-year due to the strong demand in the finance, utilities, energy, heavy industry, and manufacturing sectors, including many central government ministries and agencies. As a result, OPSWAT has doubled its headcount by adding technical engineers, sales specialists, and marketing resources.

Atsushi Takamatsu brings over 17 years of management experience in the cybersecurity industry to his new role. Prior to joining OPSWAT, Takamatsu was Managing Director of Absolute and NetMotion Software in Japan, Director of Japan for BlueCat Networks, and held senior sales management positions at Citrix Systems Japan. He is excited to lead OPSWAT Japan and contribute to protecting Japan’s critical infrastructure organizations from destructive malware and zero-day attacks.

“I am delighted to serve as Country General Manager for OPSWAT Japan, which has experienced tremendous growth over the past two years,” said Takamatsu. “I have seen a significant increase in adoption in both the public and private sectors, and working with key customers including major Japanese airlines and Japan’s nuclear industry is a testament to that. I strongly believe that 2023 will be an important milestone year that will accelerate the OPSWAT’s penetration of the OT security market in the region.”

OPSWAT will establish a CIP Lab in Tokyo in collaboration with Net One Partners K.K. to offer advanced cyber security solutions and useful training to Japanese customers and partners.

“We are very pleased with OPSWAT Japan’s significant growth in the Japanese market,” said Tenaka-san, President, CEO. “We also sincerely welcome their increased resources for future growth and business expansion. Net One Partners looks forward to further strengthening our strategic partnership with OPSWAT Japan and delivering better solutions to the market to meet the growing demand for cyber security solutions in Japan. ”

About OPSWAT  

OPSWAT is a global leader in IT, OT and ICS critical infrastructure cybersecurity solutions and Deep Content Disarm and Reconstruction (CDR), protecting the world’s mission-critical organizations from malware and zero-day attacks. To minimize the risk of compromise, OPSWAT Critical Infrastructure Protection solutions safeguard both public and private sector organizations with the latest technology, processes, and hardware scanning to secure the transfer of data, files, and device access across critical networks. More than 1,500 organizations worldwide spanning Financial Services, Defense, Manufacturing, Energy, Aerospace, and Transportation Systems trust OPSWAT to secure their files and devices; ensure compliance with industry and government-driven policies and regulations, and protect their reputation, finances, employees, and customers from cyber-driven disruption. For more information on OPSWAT, visit www.opswat.com.

Attachment

• OPSWAT Announces Rapid Business Growth and Operational Expansion in Japan with New Country General Manager Appointment

Kazuto Aoki   
OPSWAT Japan
kazuto.aoki@opswat.com

GlobeNewswire Distribution ID 8810820

April 18, 2023

Latest clinical data set of 200,000 patients from over 200 hospitals, includes pandemic data for a broader and dependable foundation for machine learning

Amsterdam, the Netherlands and Cambridge, MA, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a health technology provider, today announced an expansion of its initiative with the Institute for Medical Engineering and Science (IMES) at the Massachusetts Institute of Technology (MIT) to allow health care researchers access to a new critical care data set to help advance machine learning and artificial intelligence (AI) in healthcare. The updated eICU Collaborative Research Database (eICU-CRD) includes de-identified data of 200,000 critical care patients, including patients who were impacted by COVID-19. The broader and clinically dependable data set will support the development of solutions that improve patient care and clinical outcomes.

During the COVID-19 pandemic, eICU and critical care saw a dramatic increase of patients and unique challenges in the way that care was provided, prompting Philips and IMES to expand the original data set, first released in 2016. The new secure database includes de-identified and detailed clinical information such as vital signs, pharmacy and medication orders, laboratory results, diagnoses, and novel severity of illness scores. The dataset gives comprehensive insights on patient treatments, co-morbidities, readmissions, and clinical outcomes.

Researchers at Philips and the Laboratory of Computational Physiology within IMES will grant researchers around the world access to the data to help develop advanced algorithms and provide new insights on critical care. The Laboratory of Computational Physiology will continue to serve as the academic research hub for the initiative and will provide and maintain access, as well as help educate researchers on the database and offer a platform for collaboration. The database is available for medical research, to those who are credentialed, who take human subjects training, and who agree to a data use agreement.

“The database, which includes patient information from 2020 and 2021, now contains significant overlap with the Covid-19 pandemic, yielding valuable patient data for research,” said Leo Anthony Celi, principal research scientist and clinical research director at the Laboratory of Computational Physiology at IMES. “This updated database is a vital resource for education, including in many courses at institutions like Harvard, MIT and Stanford; and training, as well as low-resource institutions,” said Jesse D. Raffa, research scientist in the Lab for Computational Physiology at IMES.

The eICU-CRD is the only dataset containing detailed critical care data from over 200 hospitals across the U.S., representing many ‘real-world’ challenges for successful deployment of algorithms and models, which are often not readily apparent in single-center datasets. Unlike other organizations that do not share data or only share single source data sets, Philips shares its data with credentialled researchers to help advance AI for improving outcomes in human health. More than 3,000 users have used the original database with citations in over 660 published academic research papers, including in Nature, The New England Journal of Medicine and the Journal of the American Medical Association.

“This initiative demonstrates our commitment to advancing machine learning and AI efforts, by making eICU data available for global research initiatives,” said Shiv Gopalkrishnan, General Manager of EMR & Care Management at Philips. “This is how we can enhance patient care and improve clinical outcomes: liberating and connecting data across systems and applications with integrated devices, systems and informatics, which can inform research with patient insights that can help clinicians make the right decision at the right time for their patients.”

For further information, please contact:

Silvie Casanova
Philips North America
Tel.+1 781 879 0692
E-mail: silvie.casanova@philips.com

Anna Hogrebe
Philips Global Press Office
Tel.: +1 416 270 6757
E-mail: anna.hogrebe@philips.com

Mindy Blodgett
MIT IMES
Tel.+1 617 324 4019
E-mail: mblodget@mit.edu

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

About IMES
The Institute for Medical Engineering and Science (IMES) at the Massachusetts Institute of Technology (MIT) is an inclusive community of students, administrative staff, research staff, and faculty who research, work, educate, and learn, at the convergence of engineering, science, and medicine to transform human health for all. More about IMES can be found at imes.mit.edu.

Attachment

• A researcher reviews patient data

GlobeNewswire Distribution ID 1000804364

JCDC will benefit from Fortinet’s in-depth cybersecurity expertise and industry-leading threat intelligence from FortiGuard Labs

SUNNYVALE, Calif., April 18, 2023 (GLOBE NEWSWIRE) —

Ken Xie, Founder, Chairman of the Board, and Chief Executive Officer at Fortinet
“Fortinet is honored to become a member of JCDC to build on our existing collaboration and trusted relationship with the U.S. government to help improve our nation’s cybersecurity. Fortinet has a long track record of supporting mission-critical public-private partnerships and we look forward to collaborating with JCDC and sharing our expertise in cybersecurity, our broad visibility into threat activity, and the actionable threat intelligence we generate. We applaud the work JCDC has accomplished to forge cross sector collaboration since their founding in 2021 and look forward to helping JCDC mature its capabilities and contribute to building the United States’ cyber resiliency.”

News Summary 
Fortinet® (NASDAQ: FTNT), the global cybersecurity leader driving the convergence of networking and security, today announced it has become a member of the Joint Cyber Defense Collaborative (JCDC), furthering the company’s commitment to strengthening the United States’ security posture and cybersecurity resilience. The Cybersecurity and Infrastructure Security Agency (CISA) established JCDC in 2021 to bring together public and private entities with the goal to gather, analyze and share actionable information to more proactively protect and defend against cyber threats. These types of collaborative efforts help build systemic resilience by both coordinating incident response and by addressing vulnerabilities and other cyber risks before they are exploited.

Fortinet will work with JCDC to leverage the company’s more than 20 years of cybersecurity leadership and expertise, including actionable threat research from FortiGuard Labs, Fortinet’s elite threat intelligence and research organization established in 2005. FortiGuard Labs continuously monitors the worldwide attack surface using mature artificial intelligence (AI) and machine learning (ML) technology to neutralize events and issue actionable updates.

Fortinet will share this timely and actionable threat intelligence and cyber best practices with the JCDC community to prevent risks and mitigate the greatest cyber threats and vulnerabilities faced by the United States and its international partners. This collaboration further expands Fortinet’s long-standing commitment to cross-industry and cross-sector partnerships with organizations such as Interpol and the World Economic Forum’s Centre for Cybersecurity to help combat today’s most pressing cyber challenges and to disrupt cybercrime.

About Fortinet
Fortinet (NASDAQ: FTNT) is a driving force in the evolution of cybersecurity and the convergence of networking and security. Our mission is to secure people, devices, and data everywhere, and today we deliver cybersecurity everywhere you need it with the largest integrated portfolio of over 50 enterprise-grade products. Well over half a million customers trust Fortinet’s solutions, which are among the most deployed, most patented, and most validated in the industry. The Fortinet Training Institute, one of the largest and broadest training programs in the industry, is dedicated to making cybersecurity training and new career opportunities available to everyone. FortiGuard Labs, Fortinet’s elite threat intelligence and research organization, develops and utilizes leading-edge machine learning and AI technologies to provide customers with timely and consistently top-rated protection and actionable threat intelligence. Learn more at https://www.fortinet.com, the Fortinet Blog, and FortiGuard Labs.

About the Joint Cyber Defense Collaborative  
Pursuant to new authority from Congress, the Cybersecurity and Infrastructure Security Agency (CISA) established JCDC in August 2021 to transform traditional public-private partnerships into real-time private-public operational collaboration and shift the paradigm from reacting to threats and vulnerabilities to proactively planning and taking steps to mitigate them. JCDC combines the visibility, insight, and innovation of the private sector with the capabilities and authorities of the federal cyber ecosystem to collectively drive down cyber risk to the nation at scale. Learn more about JCDC at CISA.gov/JCDC.

FTNT-O

Copyright © 2023 Fortinet, Inc. All rights reserved. The symbols ® and denote respectively federally registered trademarks and common law trademarks of Fortinet, Inc., its subsidiaries and affiliates. Fortinet’s trademarks include, but are not limited to, the following: Fortinet, the Fortinet logo, FortiGate, FortiOS, FortiGuard, FortiCare, FortiAnalyzer, FortiManager, FortiASIC, FortiClient, FortiCloud, FortiMail, FortiSandbox, FortiADC, FortiAI, FortiAIOps, FortiAntenna, FortiAP, FortiAPCam, FortiAuthenticator, FortiCache, FortiCall, FortiCam, FortiCamera, FortiCarrier, FortiCASB, FortiCentral, FortiConnect, FortiController, FortiConverter, FortiCWP, FortiDB, FortiDDoS, FortiDeceptor, FortiDeploy, FortiDevSec, FortiEdge, FortiEDR, FortiExplorer, FortiExtender, FortiFirewall, FortiFone, FortiGSLB, FortiHypervisor, FortiInsight, FortiIsolator, FortiLAN, FortiLink, FortiMoM, FortiMonitor, FortiNAC, FortiNDR, FortiPenTest, FortiPhish, FortiPlanner, FortiPolicy, FortiPortal, FortiPresence, FortiProxy, FortiRecon, FortiRecorder, FortiSASE, FortiSDNConnector, FortiSIEM, FortiSMS, FortiSOAR, FortiSwitch, FortiTester, FortiToken, FortiTrust, FortiVoice, FortiWAN, FortiWeb, FortiWiFi, FortiWLC, FortiWLM and FortiXDR. Other trademarks belong to their respective owners. Fortinet has not independently verified statements or certifications herein attributed to third parties and Fortinet does not independently endorse such statements. Notwithstanding anything to the contrary herein, nothing herein constitutes a warranty, guarantee, contract, binding specification or other binding commitment by Fortinet or any indication of intent related to a binding commitment, and performance and other specification information herein may be unique to certain environments.

GlobeNewswire Distribution ID

April 18, 2023

• Healthcare leaders are heavily investing in AI or plan to do so for both critical decision support and operational efficiency, helping tackle staff shortages
• Largest global survey of its kind shows healthcare leaders continue to recognize virtual care as key to bringing care closer to patients, wherever they are

Amsterdam, the Netherlands, and Chicago, USA – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the results of its Future Health Index (FHI) 2023 report: Taking healthcare everywhere. Unveiled at HIMSS23, the eighth annual FHI 2023 global report shows healthcare leaders are increasingly prepared to invest in AI, recognize the opportunity virtual care offers to bring care closer to patients, and acknowledge the importance of building partnerships to improve care.

“Post Covid, demand for healthcare services has increased, but there are fewer healthcare professionals available to serve this growing number of patients. This year’s report shows healthcare leaders are prepared to invest in AI to alleviate this pressure on their workforce,” said Shez Partovi, Chief Innovation & Strategy Officer and Business Leader of Enterprise Informatics at Philips. “In order to genuinely relieve that burden, it’s essential that new AI capabilities are interoperable and embedded into clinical and operational workflows.”

Tackling staff shortages with digital innovation and automation
Planned investments in AI over the next three years show the biggest increase in critical decision support (39% in 2023, up from 24% in 2021). This was a top choice among cardiology (50%) and radiology (48%) leaders. The percentage of healthcare leaders planning to invest in AI for operational efficiency, including automating documentation, scheduling patients, and performing routine tasks, remained steady at 37%.

Bringing care closer to the patient, expanding access points and convenience
With moving care to new settings a key contributor to reducing staffing pressure, 70% of all respondents say virtual care has had the biggest impact on improving patient care or will in the next three years. The report also shows virtual care is moving into more areas of care, meeting patients where they are. 82% of healthcare leaders say that their facility currently provides intensive or critical care supported virtually (41%) or plans to in the next three years (41%). Virtual care also plays a vital role in attracting and retaining talent, with 44% of younger healthcare professionals indicating new care delivery models that connect different care settings are a top priority when choosing where to work.

Partnering across the healthcare ecosystem to expand the reach of care
One in three (34%) healthcare leaders are building partnerships outside their healthcare system to be able to provide the best possible care. Among their top choices of current partners are diagnostic imaging or screening centers (28%), ambulatory care centers (23%), emergency medical centers (23%), and retailers or pharmacies (22%) – all of which can also help in bringing care closer to the patient.

The FHI 2023 report is based on proprietary research among nearly 3,000 healthcare leaders and younger healthcare professionals conducted in 14 countries. To access the report, visit Future Health Index 2023.

For further information, please contact:

Meredith Amoroso
Philips Global Press Office
Tel.: +1 724-584-8991
E-mail: meredith.amoroso@philips.com

About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2022 sales of EUR 17.8 billion and employs approximately 77,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips 2023 FHI: Healthcare leaders focused on staff shortages
• Philips 2023 FHI: Healthcare leaders want to step up AI investments
• Download the 2023 Philips Future Health Index Global Report
• Philips FHI 2023 Global Findings: Infographic

GlobeNewswire Distribution ID 1000804559